Alnylam Pharmaceuticals (ALNY) News Today → Man who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.” (From InvestorPlace) (Ad) Free ALNY Stock Alerts $149.40 -1.82 (-1.20%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 4:32 AM | americanbankingnews.comShort Interest in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Grows By 5.2%May 16 at 3:55 PM | benzinga.comMarket Whales and Their Recent Bets on ALNY OptionsMay 16 at 7:56 AM | marketbeat.comJump Financial LLC Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Jump Financial LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 7,292 shares of the biopharmaceutical company's stock, valued at approximately $1,396,000. SeMay 15, 2024 | finance.yahoo.comThe Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) First-Quarter Results Are Out And Analysts Have Published New ForecastsMay 15, 2024 | finance.yahoo.comAlnylam Issues 2023 Corporate Responsibility ReportMay 14, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 19,324 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Charles Schwab Investment Management Inc. boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 4.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 438,304 shares of the biopMay 13, 2024 | americanbankingnews.comContrasting Alnylam Pharmaceuticals (NASDAQ:ALNY) & TFF Pharmaceuticals (NASDAQ:TFFP)May 11, 2024 | americanbankingnews.comQ2 2024 Earnings Forecast for Alnylam Pharmaceuticals, Inc. Issued By HC Wainwright (NASDAQ:ALNY)May 10, 2024 | fool.comAlnylam Pharmaceuticals Outperformed in Q1May 10, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to Post Q2 2024 Earnings of ($1.19) Per Share, HC Wainwright ForecastsAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Investment analysts at HC Wainwright dropped their Q2 2024 earnings per share estimates for shares of Alnylam Pharmaceuticals in a research note issued to investors on Tuesday, May 7th. HC Wainwright analyst P. Trucchio now forecasts thaMay 9, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Viridian Therapeutics (VRDN)May 9, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Raised by Segantii Capital Management LtdSegantii Capital Management Ltd lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 71.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,950 shares of the biopharmaceutical cMay 9, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Cytokinetics (CYTK)May 7, 2024 | marketbeat.comHC Wainwright Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $400.00HC Wainwright upped their price target on shares of Alnylam Pharmaceuticals from $395.00 to $400.00 and gave the company a "buy" rating in a research report on Tuesday.May 7, 2024 | finance.yahoo.comPureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive AppointmentsMay 6, 2024 | marketbeat.comLos Angeles Capital Management LLC Invests $3.26 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Los Angeles Capital Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 17,028 shares of the biopMay 3, 2024 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Issues Earnings ResultsAlnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. The company's revenue was up 54.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.40) earnings per share.May 3, 2024 | finance.yahoo.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call TranscriptMay 3, 2024 | markets.businessinsider.comStrong Financial Growth and Promising Clinical Trials Bolster Buy Rating for Alnylam PharmaceuticalsMay 3, 2024 | finance.yahoo.comAlnylam Pharmaceuticals First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at Chardan CapitalChardan Capital reissued a "buy" rating and issued a $225.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday.May 3, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Trimmed by Van ECK Associates CorpVan ECK Associates Corp reduced its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 13.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 61,233 shares of the biopharmaceutical company's stock after selling 9,853 shMay 3, 2024 | finance.yahoo.comAlnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...May 2, 2024 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)Needham & Company LLC restated a "buy" rating and set a $200.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday.May 2, 2024 | sfgate.comAlnylam: Q1 Earnings SnapshotMay 2, 2024 | investorplace.comALNY Stock Earnings: Alnylam Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | seekingalpha.comAlnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 2, 2024 | msn.comAlnylam Pharmaceuticals Non-GAAP EPS of -$0.16 beats by $0.32, revenue of $494.3M beats by $67.44MMay 2, 2024 | businesswire.comAlnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period ActivityMay 1, 2024 | markets.businessinsider.comHere's what Wall Street expects from Alnylam Pharmaceuticals's earningsApril 30, 2024 | markets.businessinsider.comAlnylam, Medison Expand Partnership To Market RNAi Therapeutics In Addnl. LATAM And APAC MarketsApril 30, 2024 | prnewswire.comMedison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including AustraliaApril 29, 2024 | insidermonkey.com5 Most Promising Stocks to Buy Before They Take OffApril 29, 2024 | marketbeat.comShort Interest in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Decreases By 10.7%Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) saw a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 2,500,000 shares, a decrease of 10.7% from the March 31st total of 2,800,000 shares. Based on an average trading volume of 836,100 shares, the short-interest ratio is currently 3.0 days.April 28, 2024 | msn.comCompare with Ironwood Pharmaceuticals Inc (IRWD)April 27, 2024 | marketbeat.comSector Gamma AS Sells 20,876 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Sector Gamma AS lessened its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 39.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,092 shares of the biopharmaceutical comApril 26, 2024 | finance.yahoo.comOligonucleotide Synthesis Market Worth $19.7 billion | MarketsandMarkets™April 26, 2024 | finanznachrichten.deOligonucleotide Synthesis Market Worth $19.7 billion | MarketsandMarketsApril 26, 2024 | markets.businessinsider.comEQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest ratesApril 25, 2024 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Reaches New 52-Week Low at $142.14Alnylam Pharmaceuticals (NASDAQ:ALNY) Hits New 52-Week Low at $142.14April 24, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Lowered by Handelsbanken Fonder ABHandelsbanken Fonder AB lessened its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 55.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 74,898 shares of the biopharmaceutical company's stock after sellingApril 22, 2024 | marketbeat.comDuality Advisers LP Buys 7,682 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Duality Advisers LP raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 81.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 17,112 shares of the biopharmaceutical company's stock after buying aApril 21, 2024 | marketbeat.comZurcher Kantonalbank Zurich Cantonalbank Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 99.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 45,080 shares of the biopharmaceutical company's stock afterApril 19, 2024 | benzinga.comHow Is The Market Feeling About Alnylam Pharmaceuticals?April 19, 2024 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 1-Year Low at $143.50Alnylam Pharmaceuticals (NASDAQ:ALNY) Hits New 1-Year Low at $143.50April 18, 2024 | businesswire.comAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial ResultsApril 17, 2024 | stocknews.com3 Biotech Stocks Paving the Way for Bullish Investment GainsApril 17, 2024 | markets.businessinsider.comLevi & Korsinsky Reminds Alnylam Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ALNYApril 14, 2024 | marketbeat.comMirae Asset Global Investments Co. Ltd. Sells 22,532 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Mirae Asset Global Investments Co. Ltd. trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 37.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 38,187 shares of the biopharmacApril 12, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. Forecasted to Earn Q1 2024 Earnings of ($1.17) Per Share (NASDAQ:ALNY)Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Stock analysts at Zacks Research lifted their Q1 2024 earnings per share estimates for Alnylam Pharmaceuticals in a research note issued to investors on Wednesday, April 10th. Zacks Research analyst A. Chakraborty now expects that the bi Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made … Click here to see the presentation now. ALNY Media Mentions By Week ALNY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALNY News Sentiment▼0.330.43▲Average Medical News Sentiment ALNY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALNY Articles This Week▼98▲ALNY Articles Average Week Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Royalty Pharma News BioMarin Pharmaceutical News United Therapeutics News Ionis Pharmaceuticals News Genmab A/S News Teva Pharmaceutical Industries News BeiGene News Viatris News Sarepta Therapeutics News Dr. Reddy's Laboratories News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALNY) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
